Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.
about
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Identification of cytomegalovirus and human herpesvirus-6 DNA in a patient with corneal endotheliitis.Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-β-producing CD39+ regulatory T cellsRisk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.Musculoskeletal disorders as underlying cause of death in 58 countries, 1986-2011: trend analysis of WHO mortality database.Comorbidity profile among patients with rheumatoid arthritis and the impact on prescriptions trend.Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report.Interleukin 6 blockage-induced neutropenia in a patient with rheumatoid arthritis and resolved hepatitis BBiological therapy and dentistry: a review paper.Biologics in oral medicine: principles of use and practical considerations.The influence of ageing on the development and management of rheumatoid arthritis.Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab.Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.Plasma levels of D-dimer in a 5-year-old girl with systemic juvenile idiopathic arthritis: A case report and literature review.Cytokines during periodontal wound healing: potential application for new therapeutic approach.Relapsing Polychondritis: A Review and Guide for the Dermatologist.Approach to the Management of Autoimmunity in Primary Immunodeficiency.Tuberculosis and biologics in rheumatology: India - A special situation.[Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].Epidemiology: The challenge of practicing rheumatology in Africa.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Survey of rheumatologists on the use of the Philippine Guidelines on the Screening for Tuberculosis prior to use of Biologic Agents.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyLatent virus reactivation risk and biological drugs: chronic inflammatory and immune-mediated disorders.Biological Response Modifiers in Rheumatoid Arthritis: Systematic Review and Meta-analysis of Safety[Screening investigations during intensified immunosuppression in children and adolescents. Part 1].Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.Immunogenicity And Persistence Of A Prime-Boost Re-Vaccination Strategy For Pneumococcal Vaccines In Patients With Rheumatoid Arthritis.Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events.Formulation and evaluation of poly(lactic-co-glycolic acid) microspheres loaded with an altered collagen type II peptide for the treatment of rheumatoid arthritis.Anti-rheumatoid activity of ethanolic extract of Sesamum indicum seed extract in Freund's complete adjuvant induced arthritis in Wistar albino rats.
P2860
Q28074148-37AF9EF5-43B6-42F2-86D2-885B61D99C09Q34514777-ED9A6AC6-8756-46F2-BF26-F9A134FC73EEQ35023513-22D59AB6-2EEA-47E3-820D-65FEF4AF61D3Q35636624-0DD2DFC0-377F-426B-A622-B2FC210322C0Q36031285-604E9217-50F2-461A-800B-EC068935F20BQ36268231-692912AE-8FB8-47EA-B41F-68166B7C6F9FQ36758324-0CB3D385-EDAB-46AC-B0CA-8A49674B8817Q36826300-70816D62-6088-44FA-9E1F-CA2B11C8F19AQ36842361-E312A22B-C0F6-49AD-AC00-3131BDDDF4ECQ37550670-9CBE97BA-7977-4ACD-ADB8-6182584A5512Q37993932-0FC9C3AB-6F43-4010-9895-ACF2543C544CQ38115131-43D68A35-5061-46F8-B205-A0B4E81A0519Q38155126-82966CF8-855A-4BB3-A420-F9D7A5C5AE81Q38157586-204D5426-E741-440F-B731-14CBF9BE2661Q38171360-57BEAA2C-DFDC-41A3-ACE4-5F10759EED27Q38719056-E1BDCB53-4D36-48F3-967C-FEB9285FD34BQ38761962-4BC9F25C-5A70-448E-AAB7-253137BC71C6Q38970527-8D2E5D9F-5A5B-468F-A7C6-132FB688BA3BQ39012945-26E05351-8F0E-4AC2-BD28-D4CBFCC6ABD9Q39449936-B730551D-E2D1-4B83-B371-660FBAA939FAQ40238572-19201D1F-0B37-402E-B975-88AA8A0CE02EQ40532298-852BE2BA-A8F5-43FE-90BD-31599C9F9B4CQ40598586-6F09B6C3-BB6C-4CB9-B057-AA8E45E4DA7CQ41143403-4164EC78-51C3-47FF-823D-2AC9C294D42DQ41176187-D089E358-4E91-4C28-8E1A-FE00D9553168Q41439263-5F0077E9-B845-4AC3-B37B-134BEADBE980Q42236159-A9424C9D-5C51-4C72-8750-7CA28798796CQ42654704-859B4E7B-DE75-4B8B-88CE-C832FA1109F9Q45182196-23DA4CE9-C7CA-41E2-A50F-5A7100929FEFQ46580884-386EE596-78DB-4A68-A8BD-8DBD453604DAQ50064384-D12C830A-B6B0-4BC9-B397-98351A960563Q51055301-D6DACBEB-EAC9-4322-A4FC-44B284F5E5BEQ51841138-EE3CD264-96CE-483D-A0A7-A3DEAB8ED7A7Q55510189-67486F78-6D0D-42CB-BC9B-0B552D463554
P2860
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Choice of Biologic Therapy for ...... is: The Infection Perspective.
@ast
Choice of Biologic Therapy for ...... is: The Infection Perspective.
@en
type
label
Choice of Biologic Therapy for ...... is: The Infection Perspective.
@ast
Choice of Biologic Therapy for ...... is: The Infection Perspective.
@en
prefLabel
Choice of Biologic Therapy for ...... is: The Infection Perspective.
@ast
Choice of Biologic Therapy for ...... is: The Infection Perspective.
@en
P2860
P1476
Choice of Biologic Therapy for ...... is: The Infection Perspective.
@en
P2860
P356
10.2174/157339711794474620
P577
2011-02-01T00:00:00Z